Abstract:Non‐infectious uveitis has a range of ocular and systemic autoimmune and autoinflammatory causes. When the retina is involved, blood‐retinal barrier breakdown can lead to vision loss. Specific cytokines stand out as promoting intraocular inflammation. This article reviews the involvement of inflammatory cytokines – including tumour necrosis factor (TNF)‐α, interleukin (IL)‐1β, IL‐6, IL‐8, IL‐17 and chemokine C‐C motif ligand (CCL)2 – in non‐infectious uveitis. Their levels in ocular fluids, their effects on the endothelial barrier, and the results of clinical treatment trials are discussed. Characterised by intraocular inflammation, non‐infectious uveitis includes a large group of autoimmune and autoinflammatory diseases that either involve the eye alone or have both ocular and systemic manifestations. When non‐infectious uveitis involves the posterior segment of the eye, specifically the retina, there is substantial risk of vision loss, often linked to breakdown of the inner blood‐retinal barrier. This barrier is formed by non‐fenestrated retinal vascular endothelial cells, reinforced by supporting cells that include pericytes, Müller cells and astrocytes. Across the published literature, a group of inflammatory cytokines stand out as prominent mediators of intraocular inflammation, with effects on the retinal endothelium that may contribute to breakdown of the inner blood‐retinal barrier, namely tumour necrosis factor (TNF)‐α, interleukin (IL)‐1β, IL‐6, IL‐8, IL‐17 and chemokine C‐C motif ligand (CCL)2. This article reviews the function of each cytokine and discusses the evidence for their involvement in retinal endothelial barrier dysfunction in non‐infectious uveitis, including basic laboratory investigations, studies of ocular fluids collected from patients with non‐infectious uveitis, and results of clinical treatment trials. The review also outlines gaps in knowledge in this area. Understanding the disease processes at a molecular level can suggest treatment alternatives that are directed against appropriate biological targets to protect the posterior segment of eye and preserve vision in non‐infectious uveitis.

Ulcerative colitis and autoimmune uveitis. Case report

An Experimental Autoimmune Uveoretinitis Model and Intraocular Inflammation

Ophthalmological Manifestations in Inflammatory Bowel Diseases: Keep an Eye on It

Ocular manifestations of inflammatory bowel diseases: an update for gastroenterologists

Autoimmunity in uveitis

Clinical and Functional Evaluation of Ocular Inflammatory Disease Using the Model of Experimental Autoimmune Uveitis.

Cancer Immunotherapy and Uveitis: Balancing Anti-Tumor Immunity and Ocular Autoimmunity

Ocular, Auricular, and Oral Manifestations of Inflammatory Bowel Disease

Autoimmune Diseases and Retina

P459 The prevalence and characteristics of inflammatory bowel disease-related ocular involvement in children

Prevalence and clinical features of chronic uveitis in pediatric inflammatory bowel diseases: A nationwide study

[Ocular involvement in rheumatoid arthritis, connective tissue diseases and vasculitis]

Ocular microvascular damage in autoimmune rheumatic diseases: The pathophysiological role of the immune system

Autoimmune uveitis: clinical, pathogenetic, and therapeutic features

Autoimmune uveitis in Behçet's disease and Vogt-Koyanagi-Harada disease differ in tissue immune infiltration and T cell clonality

Ocular involvement in adult and paediatric patients with monogenic autoinflammatory diseases: a Spanish multicentre retrospective study

Microbiome and Autoimmune Uveitis

Ocular endothelial dysfunction in pediatric inflammatory bowel disease

Inflammatory cytokines as mediators of retinal endothelial barrier dysfunction in non‐infectious uveitis

The history of uveitis: from antiquity to the present day

Update on ocular manifestations of the main monogenic and polygenic autoinflammatory diseases